Novus Biologicals products are now on bio-techne.com

CD55/DAF Antibody [Unconjugated]

Images

 
CD55/DAF was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line (left panel, positive staining) and MOLT-4 human acute lymphoblastic leukemia cell line (right panel, negative staining) using ...read more
CD55/DAF was detected in immersion fixed paraffin-embedded sections of human colon cancer tissue using 15 µg/mL Goat Anti-Human CD55/DAF Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2009) overnight at 4 ...read more

Product Details

Summary
Reactivity HuSpecies Glossary
Applications IHC, ICC/IF
Clonality
Polyclonal
Host
Goat
Conjugate
Unconjugated
Concentration
LYOPH

Order Details

View Available Conjugates
Catalog# & Conjugate Size Price
View Available Formulations
Catalog# & Formulation Size Price

CD55/DAF Antibody [Unconjugated] Summary

Immunogen
Mouse myeloma cell line NS0-derived recombinant human CD55/DAF
Asp35-Ser353
Accession # P08174
Specificity
Detects human CD55/DAF in direct ELISAs and Western blots.
Source
N/A
Isotype
IgG
Clonality
Polyclonal
Host
Goat
Gene
CD55
Purity Statement
Antigen Affinity-purified
Innovator's Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.

Applications/Dilutions

Dilutions
  • Immunocytochemistry 0.5-15 ug/mL
  • Immunohistochemistry 5-15 ug/mL
Publications
Read Publications using
AF2009 in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Preservative
No Preservative
Concentration
LYOPH
Reconstitution Instructions
Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD55/DAF Antibody [Unconjugated]

  • CD55 antigen
  • CD55 molecule, decay accelerating factor for complement (Cromer blood group)
  • CD55
  • CR
  • CRdecay accelerating factor for complement (CD55, Cromer blood group system)
  • CROMDAFcomplement decay-accelerating factor
  • DAF
  • decay accelerating factor for complement
  • TC

Background

CD55, also known as DAF or decay-accelerating factor, is a 70‑75 kDa member of the RCA family of proteins. Human RCA (regulators of complement/C’ activation) proteins are products of chromosome 1 genes that are ubiquitously expressed on cells exposed to plasma complement proteins (1‑4). A hallmark of RCA proteins is the presence of four to 30 SCRs (short consensus repeats; also called CCPs for C’ control protein modules) in their plasma-exposed regions. SCRs are characterized by a 60‑65 amino acid (aa) module that contains a highly conserved Trp residue and two internal disulfide bonds that create a beta -barrel structure (1). Human CD55 is synthesized as a 381 aa precursor that contains a 34 aa signal sequence, a 319 aa mature region and a 28 aa C-terminal prosegment (5, 6). The mature region contains four SCR modules and a C-terminal O-glycosylated extension (7). Following cleavage of the prosegment, a serine is exposed that serves as an anchor for a GPI-linkage (8). Multiple polymorphisms are found in the molecule. Alternate splicing also exists. One form that may not be translated shows an intron insertion in the prosegment, resulting in a 79 aa substitution for the standard C-terminal 20 aas of the prosegment (6). Another form generates a truncated 199 aa precursor that cannot be membrane-bound and may not be secreted (9). Mature CD55 is 53% and 84% aa identical to mouse and monkey CD55, respectively. CD55 is known to bind CD97 via the first SCR (4). It also binds physiologically-generated C3 convertases with its second and third SCRs (7, 10). Binding results in an accelerated “decay”, or dissociation of active C3 convertases, thus blocking the development of C’ attack complexes on nonforeign cells (1, 2). Finally, viruses and bacteria are also known to utilize multiple SCR sites for infection (4).

  1. Herbert, A. et al. (2002) Biochem. Soc. Trans. 30:990. 
  2. Miwa, T. and W-C. Song (2001) Int. Immunopharmacol. 1:445. 
  3. Hourcade, D. et al. (2000) Immunopharmacology 49:103. 
  4. Lea, S. (2002) Biochem. Soc. Trans. 30:1014. 
  5. Medof, M.E. et al. (1987) Proc. Natl. Acad. Sci. USA 84:2007. 
  6. Caras, I.W. et al. (1987) Nature 325:545.
  7. Lukacik, P. et al. (2004) Proc. Natl. Acad. Sci. USA 101:1279.
  8. Moran, P. et al. (1991) J. Biol. Chem. 266:1250.
  9. Lublin, D.M. et al. (1994) Blood 84:1276.
  10. Williams, P. et al. (2003) J. Biol. Chem. 278:10691.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customers Who Viewed This Item Also Viewed...

H00003347-M01
Species: Hu
Applications: ELISA, ICC/IF, S-ELISA, WB
AF1107
Species: Mu
Applications: IHC, WB
7268-CT
Species: Hu
Applications: BA
NB100-524
Species: Hu, Mu
Applications: Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
NBP2-79843
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, WB
NBP2-34294
Species: Hu, Mu, Rt
Applications: Flow, IHC, IHC-P
NB500-330
Species: Hu
Applications: B/N, CyTOF-ready, Flow, IHC, IHC-Fr, IHC-P, IP
AF2005
Species: Hu
Applications: CyTOF-ready, Flow, IHC, WB
MAB1417
Species: Bv, Hu, Mu
Applications: CyTOF-ready, ICC, IHC, ICFlow
NB200-540
Species: Ec, Mu
Applications: CyTOF-ready, Flow-IC, Flow, IA, ICC/IF, IHC, IHC-Fr, IHC-P, IP
MAB1455
Species: Hu
Applications: CyTOF-ready, Dual ISH-IHC, ICC, IHC, ICFlow, Simple Western, WB
DY1707
Species: Hu
Applications: ELISA
NBP1-47974
Species: Ca, Hu, Pm, Rt
Applications: Flow, ICC/IF, IHC, IHC-P, WB
NBP2-20383
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P, WB
NBP1-90214
Species: Hu
Applications: ICC/IF, IHC, IHC-P, WB
NBP2-37477
Species: Hu
Applications: ELISA, ICC/IF, IHC, IHC-P, WB
AF3398
Species: Hu, Mu, Rt
Applications: ICC, KO, Simple Western, WB
NBP2-52979
Species: Hu, Mu
Applications: Flow, ICC/IF, IHC, IHC-P, WB
AF2009
Species: Hu
Applications: IHC, ICC/IF

Publications for CD55/DAF Antibody (AF2009)(8)

We have publications tested in 1 confirmed species: Human.

We have publications tested in 3 applications: ICC, IHC-Fr, Western Blot.


Filter By Application
ICC
(3)
IHC-Fr
(1)
Western Blot
(1)
All Applications
Filter By Species
Human
(5)
All Species
Showing Publications 1 - 8 of 8.
Publications using AF2009 Applications Species
Franke V, Meyer S, Schulze-Tanzil GG et al. Complement Regulation in Immortalized Fibroblast-like Synoviocytes and Primary Human Endothelial Cells in Response to SARS-CoV-2 Nucleocapsid Protein and Pro-Inflammatory Cytokine TNFa Life (Basel, Switzerland) 9/30/2022 [PMID: 36294967]

Details:
Dilutuion used in ICC 1:50
S Silawal, B Kohl, J Shi, G Schulze-Ta Complement Regulation in Human Tenocytes under the Influence of Anaphylatoxin C5a International Journal of Molecular Sciences, 2021-03-18;22(6):. 2021-03-18 [PMID: 33803624] (ICC, Human) ICC Human
J Fisher, OE Sørensen, AHA Abu-Humaid Using chemiluminescence imaging of cells (CLIC) for relative protein quantification Sci Rep, 2020-10-26;10(1):18280. 2020-10-26 [PMID: 33106566] (ICC, Human) ICC Human
Derek Leaderer, Siobhan M. Cashman, Rajendra Kumar-Singh Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59 The Journal of Gene Medicine 11/9/2015 [PMID: 25917932]
Kim H, Kim K, Kim B, Cho M, Lee S The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis. PLoS ONE, 2015-04-20;10(4):e0124909. 2015-04-20 [PMID: 25894998] (IHC-Fr, Human) IHC-Fr Human
Christophe J. Queval, Valérie Nicolas, Isabelle Beau Role of Src Kinases in Mobilization of Glycosylphosphatidylinositol-Anchored Decay-Accelerating Factor by Dr Fimbria-Positive Adhering Bacteria Infection and Immunity 7/1/2011 [PMID: 21518786]
Semiramoth N, Gleizes A, Turbica I, Sandre C, Gorges R, Kansau I, Servin A, Chollet-Martin S Escherichia coli type 1 pili trigger late IL-8 production by neutrophil-like differentiated PLB-985 cells through a Src family kinase- and MAPK-dependent mechanism. J. Leukoc. Biol., 2008-11-17;85(2):310-21. 2008-11-17 [PMID: 19015376] (Western Blot, Human) Western Blot Human
Zen K, Chen CX, Chen YT, Wilton R, Liu Y Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium. J. Immunol., 2007-02-15;178(4):2483-90. 2007-02-15 [PMID: 17277156] (ICC, Human) ICC Human

Reviews for CD55/DAF Antibody (AF2009) (0)

There are no reviews for CD55/DAF Antibody (AF2009). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for CD55/DAF Antibody (AF2009) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.
mFluor Violet Conjugated Antibodies

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our CD55/DAF Antibody [Unconjugated] and receive a gift card or discount.

Bioinformatics

Gene Symbol CD55
Uniprot